S'abonner

Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial - 03/08/18

Doi : 10.1016/S1470-2045(18)30322-X 
Mark M Souweidane, ProfMD a, i, j, , Kim Kramer, ProfMD b, j, Neeta Pandit-Taskar, ProfMD c, g, k, Zhiping Zhou, PhD b, i, Sofia Haque, MD d, k, Pat Zanzonico, PhD d, e, Jorge A Carrasquillo, ProfMD c, g, k, Serge K Lyashchenko, PharmD d, f, k, Sunitha B Thakur, PhD d, e, Maria Donzelli, MSN b, Ryan S Turner, BS b, Jason S Lewis, ProfPhD d, f, k, l, Nai-Kong V Cheung, ProfMD b, Steven M Larson, ProfMD c, g, h, k, Ira J Dunkel, ProfMD b, j
a Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA 
b Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA 
c Department of Radiology, Molecular Imaging and Therapy (Nuclear Medicine) Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA 
d Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA 
e Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA 
f Radiochemistry & Molecular Imaging Probes Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA 
g Center for Targeted Radioimmunotherapy and Theranostics, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA 
h Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY, USA 
i Department of Neurological Surgery, Weill Medical College of Cornell University, New York, USA 
j Department of Pediatrics, Weill Medical College of Cornell University, New York, USA 
k Department of Radiology, Weill Medical College of Cornell University, New York, USA 
l Pharmacology Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY, USA 

* Correspondence to: Prof Mark M Souweidane, Department of Neurological Surgery, Weill Medical College of Cornell University, New York, NY 10065, USA Department of Neurological Surgery Weill Medical College of Cornell University New York NY 10065 USA

Summary

Background

Diffuse intrinsic pontine glioma is one of the deadliest central nervous system tumours of childhood, with a median overall survival of less than 12 months. Convection-enhanced delivery has been proposed as a means to efficiently deliver therapeutic agents directly into the brainstem while minimising systemic exposure and associated toxic effects. We did this study to evaluate the safety of convection-enhanced delivery of a radioimmunotherapy agent targeting the glioma-associated B7-H3 antigen in children with diffuse intrinsic pontine glioma.

Methods

We did a phase 1, single-arm, single-centre, dose-escalation study at the Memorial Sloan Kettering Cancer Center (New York, NY, USA). Eligible patients were aged 3–21 years and had diffuse intrinsic pontine glioma as diagnosed by consensus of a multidisciplinary paediatric neuro-oncology team; a Lansky (patients <16 years of age) or Karnofsky (patients ≥16 years) performance score of at least 50 at study entry; a minimum weight of 8 kg; and had completed external beam radiation therapy (54·0–59·4 Gy at 1·8 Gy per fraction over 30–33 fractions) at least 4 weeks but no more than 14 weeks before enrolment. Seven dose-escalation cohorts were planned based on standard 3 + 3 rules: patients received a single infusion of 9·25, 18·5, 27·75, 37, 92·5, 120·25, or 148 MBq, respectively, at a concentration of about 37 MBq/mL by convection-enhanced delivery of the radiolabelled antibody [124I]-8H9. The primary endpoint was identification of the maximum tolerated dose. The analysis of the primary endpoint was done in the per-protocol population (patients who received the full planned dose of treatment), and all patients who received any dose of study treatment were included in the safety analysis. This study is registered with ClinicalTrials.gov, number NCT01502917, and is ongoing with an expanded cohort.

Findings

From April 5, 2012, to Oct 8, 2016, 28 children were enrolled and treated in the trial, of whom 25 were evaluable for the primary endpoint. The maximum tolerated dose was not reached as no dose-limiting toxicities were observed. One (4%) of 28 patients had treatment-related transient grade 3 hemiparesis and one (4%) had grade 3 skin infection. No treatment-related grade 4 adverse events or deaths occurred. Estimated volumes of distribution (Vd) were linearly dependent on volumes of infusion (Vi) and ranged from 1·5 to 20·1 cm3, with a mean Vd/Vi ratio of 3·4 (SD 1·2). The mean lesion absorbed dose was 0·39 Gy/MBq 124I (SD 0·20). Systemic exposure was negligible, with an average lesion-to-whole body ratio of radiation absorbed dose higher than 1200.

Interpretation

Convection-enhanced delivery in the brainstem of children with diffuse intrinsic pontine glioma who have previously received radiation therapy seems to be a rational and safe therapeutic strategy. PET-based dosimetry of the radiolabelled antibody [124I]-8H9 validated the principle of using convection-enhanced delivery in the brain to achieve high intra-lesional dosing with negligible systemic exposure. This therapeutic strategy warrants further development for children with diffuse intrinsic pontine glioma.

Funding

National Institutes of Health, The Dana Foundation, The Cure Starts Now, Solving Kids’ Cancer, The Lyla Nsouli Foundation, Cookies for Kids’ Cancer, The Cristian Rivera Foundation, Battle for a Cure, Cole Foundation, Meryl & Charles Witmer Charitable Foundation, Tuesdays with Mitch Charitable Foundation, and Memorial Sloan Kettering Cancer Center.

Le texte complet de cet article est disponible en PDF.

Plan


© 2018  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 19 - N° 8

P. 1040-1050 - août 2018 Retour au numéro
Article précédent Article précédent
  • Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial
  • Paul C Lyon, Michael D Gray, Christophoros Mannaris, Lisa K Folkes, Michael Stratford, Leticia Campo, Daniel Y F Chung, Shaun Scott, Mark Anderson, Robert Goldin, Robert Carlisle, Feng Wu, Mark R Middleton, Fergus V Gleeson, Constantin C Coussios
| Article suivant Article suivant
  • Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study
  • Geoffrey D Coughlin, John W Yaxley, Suzanne K Chambers, Stefano Occhipinti, Hema Samaratunga, Leah Zajdlewicz, Patrick Teloken, Nigel Dunglison, Scott Williams, Martin F Lavin, Robert A Gardiner

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.